

Edgar Filing: INTERNATIONAL ISOTOPES INC - Form 10QSB

INTERNATIONAL ISOTOPES INC  
Form 10QSB  
July 30, 2003

FORM 10-QSB

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D. C. 20549

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended  
June 30, 2003

Commission file number:  
0-22923

INTERNATIONAL ISOTOPES INC.

-----  
(Exact name of registrant as specified in its charter)

Texas

74-2763837

-----  
(State of incorporation)

-----  
(IRS Employer Identification Number)

4137 Commerce Circle, Idaho Falls, Idaho

83401

-----  
(Address of principal executive offices)

-----  
(zip code)

208-524-5300

-----  
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES [X] NO [ ]

As of July 22, 2003 the number of shares of Common Stock, \$.01 par value, outstanding was 95,572,893.

INTERNATIONAL ISOTOPES INC.

TABLE OF CONTENTS

Edgar Filing: INTERNATIONAL ISOTOPES INC - Form 10QSB

Page No.

PART I - FINANCIAL INFORMATION:

Item 1 - Financial Statements:

Condensed Consolidated Balance Sheets at June 30, 2003  
(unaudited) and December 31, 2002 3

Unaudited Condensed Consolidated Statements of  
Operations for the Three Months Ended June 30, 2003  
and 2002, and for the Six Months Ended June 30, 2003  
and 2002 4

Unaudited Condensed Consolidated Statements of Cash  
Flows for the Six Months Ended June 30, 2003 and 2002 5

Notes to Unaudited Condensed Consolidated Financial  
Statements 6

Item 2 - Management's Discussion and Analysis of Financial  
Condition and Results of Operations 10

Item 3 - Controls and Procedures 12

PART II - OTHER INFORMATION:

Item 6 - Exhibits and Reports on Form 8-K 12

SIGNATURES 13

2

Part I. Financial Statements  
Item 1. Financial Statements

INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES  
Condensed Consolidated Balance Sheets

| Assets                             | June 30,<br>2003<br>(unaudited) |
|------------------------------------|---------------------------------|
| -----                              | -----                           |
| Current assets:                    |                                 |
| Cash and cash equivalents          | \$ 824,518                      |
| Accounts receivable                | 213,812                         |
| Assets held for sale               | --                              |
| Inventories                        | 2,133,969                       |
| Prepays and other current assets   | 101,985                         |
|                                    | -----                           |
| Total current assets               | 3,274,284                       |
| Property, plant and equipment, net | 312,330                         |
|                                    | -----                           |

Edgar Filing: INTERNATIONAL ISOTOPES INC - Form 10QSB

|   |                       |
|---|-----------------------|
| Total assets  | \$ 3,586,614<br>===== |
| Liabilities, Mandatorily Redeemable Preferred Stock<br>and Stockholders' Deficit  |                       |
| -----   |                       |
| Current liabilities   |                       |
| Accounts payable  | \$ 215,552            |
| Deferred revenue  | 88,872                |
| Accrued liabilities   | 142,722               |
| Note payable related to assets held for sale  | --                    |
| Current installments of mortgage and notes payable to banks   | 1,717,107             |
|   | -----                 |
| Total current liabilities   | 2,164,253             |
| Mortgage and notes payable to banks, excluding current installments   | 924,290               |
|   | -----                 |
| Total liabilities   | 3,088,543             |
| Mandatorily redeemable preferred stock, \$0.01 par value; 5,000,000 shares authorized; 850 shares issued and outstanding; liquidation value \$850,000 | 850,000               |
| Stockholders' deficit   |                       |
| Common stock, \$0.01 par value; 250,000,000 shares authorized, 95,572,893 and 95,581,135 shares issued and outstanding respectively                   | 955,730               |
| Additional paid-in capital  | 86,416,084            |
| Accumulated deficit   | (87,723,743)          |
|   | -----                 |
| Total stockholders' deficit   | (351,929)             |
|   | -----                 |
| Total liabilities and stockholders' deficit   | \$ 3,586,614<br>===== |

See accompanying notes to condensed consolidated financial statements.

3

INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES  
Unaudited Condensed Consolidated Statements of Operations

|  | Three Months ended June 30, |            | Six Mon   |
|--|-----------------------------|------------|-----------|
|  | 2003                        | 2002       | 2003      |
|  | -----                       | -----      | -----     |
| Revenues                               | \$ 785,262                  | \$ 624,084 | \$ 1,144, |
| Cost of revenues                       | 430,567                     | 371,422    | 641,      |
|  | -----                       | -----      | -----     |
| Gross profit                           | 354,695                     | 252,662    | 503,      |
|  | -----                       | -----      | -----     |
| Operating costs and expenses:          |                             |            |           |
| Salaries and contract labor            | 110,982                     | 117,765    | 213,      |
| General, administrative and consulting | 290,552                     | 425,654    | 576,      |

Edgar Filing: INTERNATIONAL ISOTOPES INC - Form 10QSB

|  |             |            |          |
|--|-------------|------------|----------|
| Total operating expenses   | 401,534     | 543,419    | 790,     |
| Operating loss   | (46,839)    | (290,757)  | (287,    |
| Other income (expense):  |             |            |          |
| Other income   | 20,867      | 563,829    | 33,      |
| Interest income  | 1,402       | --         | 2,       |
| Interest expense   | (50,281)    | (44,669)   | (82,     |
| Earnings (loss) from continuing operations                             | (74,851)    | 228,403    | (333,    |
| Preferred stock dividend, deemed dividend<br>and accretion of discount | --          | --         | -        |
| Net profit (loss) applicable to common shareholders                    | \$ (74,851) | \$ 228,403 | \$ (333, |
| Net profit (loss) per common share                                     |             |            |          |
| Basic  | \$ --       | \$ --      | \$ --    |
| Diluted  | \$ --       | \$ --      | \$ --    |

See accompanying notes to condensed consolidated financial statements.

4

INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES  
Unaudited Condensed Consolidated Statements of Cash Flows

|  | Six Months ended June 30<br>2003 | 2002    |
|--|----------------------------------|---------|
|  | -----                            | -----   |
| Cash flows from operating activities:  |                                  |         |
| Net earnings (loss)  | \$ (333,578)                     | \$ 259, |
| Adjustments to reconcile net earnings (loss) to net<br>cash used in operating activities |                                  |         |
| Depreciation and amortization  | 44,159                           | 38,     |
| Release of contingent debt   | --                               | (500,   |
| Changes in operating assets and liabilities:   |                                  |         |
| Accounts receivable  | 5,111                            | (121,   |
| Prepays and other assets   | 26,845                           | 241,    |
| Inventories  | 145,859                          | 213,    |
| Accounts payable and accrued liabilities   | (241,593)                        | 58,     |
| Checks written in excess of cash in bank   | --                               | (101,   |
| Deferred revenue   | 88,872                           | --      |
| Net cash provided by (used in) operating activities                                      | (264,325)                        | 88,     |
| Cash flows from investing activities:  |                                  |         |
| Purchase of property, plant and equipment  | (102,913)                        | (26,    |
| Proceeds from sale of assets held for sale   | 262,235                          | --      |

Edgar Filing: INTERNATIONAL ISOTOPES INC - Form 10QSB

|   |            |        |
|---|------------|--------|
| Net cash provided by (used in) investing activities     | 159,322    | (26)   |
| Cash flows from financing activities:                   |            |        |
| Repurchase of preferred stock                           | --         | (86)   |
| Proceeds from issuance of debt                          | 743,500    | 20     |
| Principal payments on debt                              | (255,883)  | (32)   |
| Net cash (used in) provided by financing activities     | 487,617    | (99)   |
| Net increase (decrease) in cash and cash equivalents    | 382,614    | (37)   |
| Cash and cash equivalents at beginning of period        | 441,904    | 293    |
| Cash and cash equivalents at end of period              | \$ 824,518 | \$ 256 |
| Supplemental disclosure of cash flow activities:        |            |        |
| Cash paid for interest                                  | \$ 118,183 | \$ 97  |
| Supplemental disclosure of noncash transactions:        |            |        |
| Acquisition of equipment for note payable               | \$ 17,523  | \$     |
| Sale of assets held for sale through assumption of debt | 345,295    |        |
| Common stock issued in preferred stock conversion       | --         | 16,080 |
| Conversion of accrued interest to notes payable         | --         | 132    |

See accompanying notes to condensed consolidated financial statements

5

INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES  
Notes to Unaudited Condensed Consolidated Financial Statements

(1) The Company and Basis of Presentation

International Isotopes Inc. (the Company) was incorporated in Texas in 1995. The Company is focused primarily on generating revenues from manufacturing nuclear medicine calibration and reference standards, processing Topaz Gemstones, and the production of High Specific Activity (HSA) cobalt from a Department of Energy test reactor (ATR). As of June 30, 2003, the Company had 11 full time employees.

Principles of Consolidation - The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Gazelle Realty, Inc. and International Isotopes Idaho, Inc. All significant intercompany accounts and transactions have been eliminated in consolidation.

Interim Financial Information - The accompanying unaudited condensed

## Edgar Filing: INTERNATIONAL ISOTOPES INC - Form 10QSB

consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and notes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments and reclassifications considered necessary for a fair and comparable presentation have been included and are of a normal recurring nature. Operating results for the six-month period ended June 30, 2003 are not necessarily indicative of the results that may be expected for the year ending December 31, 2003. The accompanying financial statements should be read in conjunction with the Company's most recent audited financial statements.

Stock-based Compensation Plans - The Company accounts for stock options issued to directors, officers and employees under Accounting Principles Board Opinion No. 25 and related interpretations ("APB 25"). Under APB 25, compensation expense is recognized if an option's exercise price on the measurement date is below the fair value of the Company's common stock. For options that provide for cashless exercise or that have been modified, the measurement date is considered the date the options are exercised or expire. Those options are accounted for as variable options with compensation adjusted each period based on the difference between the market value of the common stock and the exercise price of the options at the end of the period. The Company accounts for options and warrants issued to non-employees at their fair value in accordance with SFAS No. 123, "Accounting for Stock-Based Compensation" ("SFAS 123").

No compensation cost has been recognized for its stock options in the accompanying consolidated financial statements. Had the Company determined compensation cost based on the fair value at the grant date for its stock options under SFAS No. 123, the Company's net loss applicable to common shareholders would have been increased to the pro forma amounts indicated below for the six months ended June 30, 2003 and 2002:

|   | For the Six Months Ended<br>June 30, |              |
|---|--------------------------------------|--------------|
|   | 2003                                 | 2002         |
|   | -----                                | -----        |
| Net loss applicable to common shareholders,<br>as reported  | \$ (333,578)                         | \$ (89,894)  |
| Deduct: Total stock-based employee compensation<br>expense determined under fair value based<br>method for all awards | (54,738)                             | (103,756)    |
|   | -----                                | -----        |
| Pro forma net loss applicable to common shareholders  | \$ (388,316)                         | \$ (193,650) |
|   | =====                                | =====        |
| Basic and diluted loss per common share as reported   | \$ (0.00)                            | \$ (0.00)    |
|   | =====                                | =====        |
| Basic and diluted loss per common share pro forma   | \$ (0.00)                            | \$ (0.00)    |
|   | =====                                | =====        |

Recent Accounting Pronouncements - In May 2003 the FASB issued SFAS No. 150,

## Edgar Filing: INTERNATIONAL ISOTOPES INC - Form 10QSB

"Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity", which requires that certain financial instruments be presented as liabilities that were previously presented as equity or as temporary equity. Such instruments include mandatory redeemable preferred and common stock, and certain options and warrants. SFAS 150 is effective for financial instruments entered into or modified after May 31, 2003 and is generally effective at the beginning of the first interim period beginning after June 15, 2003. The Company adopted SFAS 150 at July 1, 2003 which will require the Company to reclassify its 850 shares of mandatorily redeemable preferred stock with a redemption value and carrying amount of \$850,000 from temporary equity to long-term liabilities. The adoption of this standard will have no effect on net loss.

In November 2002, the FASB issued Financial Interpretation No. 45, "Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others." FIN 45 sets forth the disclosures required to be made by a guarantor in its financial statements about its obligations under certain guarantees that it has issued. It also clarifies that a guarantor is required to recognize, at the inception of a guarantee, a liability for the fair value of the obligation undertaken in issuing the guarantee. The Company adopted the requirements FIN 45 in the accompanying financial statements.

### (2) Current Developments and Liquidity

Business Condition - Since inception, the Company has suffered substantial losses. During the period ended June 30, 2003 the Company had a loss of \$333,578. During the period ended June 30, 2002, the Company had earnings before preferred dividends of \$259,348. During the period ended June 30, 2003, the Company's operations used cash of \$264,325 in operating activities. During the period ended June 30, 2002, the Company's operations provided cash from operating activities of \$88,472. Management expects to generate sufficient cash flows to meet operational needs during the remainder of 2003 through financing and operating capital; however, there is no assurance that these cash flows will occur.

7

### (3) Net Loss Per Common Share - Basic and Diluted

Basic earnings (loss) per share excludes dilution for potentially dilutive securities and is computed by dividing earnings (loss) applicable to common stockholders by the weighted average number of common shares outstanding during the period.

Diluted earnings (loss) per share, which is computed on the basis of the weighted average number of common shares and all potentially dilutive securities outstanding during the period, factors in potentially dilutive securities and adding back any convertible dividend (except if the effect is anti-dilutive). The computation of basic and diluted earnings (loss) per share is as follows:

|  | For the Three Months Ended<br>June 30, 2003 | June 30, 2002 |  | For the S<br>June 30, 200 |
|--|---|---------------|--|---------------------------|
|  | -----                                       | -----         |  | -----                     |
| Profit (loss) from continuing operations | \$ (74,851)                                 | \$ 228,403    |  | \$ (333,57                |

Edgar Filing: INTERNATIONAL ISOTOPES INC - Form 10QSB

|   |             |             |             |
|---|-------------|-------------|-------------|
| Convertible preferred stock dividend, deemed dividend and accretion of discount | -           | -           |             |
| Net profit (loss) applicable to common shares                                   | \$ (74,851) | \$ 228,403  | \$ (333,57) |
| -----   |             |             |             |
| Basic EPS   |             |             |             |
| -----   |             |             |             |
| Weighted average common shares outstanding during the period                    | 95,572,393  | 95,081,135  | 95,576,49   |
| Net profit (loss) per common share - basic                                      | \$ -        | \$ -        | \$ -        |
| -----   |             |             |             |
| Diluted EPS   |             |             |             |
| -----   |             |             |             |
| Weighted average common shares outstanding during the period - basic            | 95,572,393  | 95,081,135  | 95,576,49   |
| Dilutive effect of stock options  | N/A         | 9,388,889   | N/A         |
| Dilutive effect of Series A and B convertible preferred stock                   | N/A         | 4,750,000   | N/A         |
| Weighted average common shares - diluted  | 95,572,393  | 109,220,024 | 95,576,49   |
| Net profit (loss) per common share - diluted                                    | \$ -        | \$ -        | \$ -        |
| =====   |             |             |             |

For the three and six months ended June 30, 2003 there were 16,000,000 options and warrants to acquire common stock, 850 Series B shares of redeemable convertible preferred stock not included in the computation of diluted net loss per share as their effect would have been anti-dilutive.

For the six months ended June 30, 2002 there were 17,746,646 options to acquire common stock, 950 Series B shares of redeemable convertible preferred stock and \$349,242 in convertible preferred dividends which were not included in the computation of diluted net loss per share as their effect would have been anti-dilutive.

(4) Inventories

Inventories consist of the following at June 30, 2003 and December 31, 2002

|                  | June 30, 2003 | December 31, 2002 |
|------------------|---------------|-------------------|
|                  | -----         | -----             |
| Raw materials    | \$ 268,359    | \$ 294,662        |
| Work in progress | 1,854,592     | 1,971,551         |
| Finished goods   | 11,018        | 13,615            |
|                  | -----         | -----             |
|                  | \$ 2,133,969  | \$ 2,279,828      |
|                  | =====         | =====             |

(5) Notes Payable

In January 2003, the Company entered into an agreement to sell the Waxahachie



## Edgar Filing: INTERNATIONAL ISOTOPES INC - Form 10QSB

real estate for the assumption of the \$345,295 debt associated with the property. As a result of the debt assumption, the Company remains liable on the note with Texas State Bank for the remainder of the term should the purchaser default on this note.

In accordance with Financial Accounting Standards Board Interpretation No. 45, Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others, the Company has recognized a \$10,000 obligation under the guarantee that consists of the obligation to stand ready to reassume the note held at Texas State Bank in the event the purchaser defaults on the note. The obligation is based on the cost necessary for the purchaser to refinance the note, which would release the Company from the guarantor position. Should the purchaser default on the note and the Company reassume the liability, they would also regain the real estate.

During the quarter ended June 30, 2003, as part of an agreement with certain shareholders, the Company increased its short-term borrowing from these shareholders to \$823,500, the notes bear interest at 5% and are due December 31, 2003.

### (6) Stockholders' Equity and Warrants

During the quarter ended March 31, 2003, as part of a licensing and manufacturing settlement agreement, Bracco Diagnostics returned 8,242 shares of the Company's common stock. The shares were immediately canceled.

During the six months ended June 30, 2003, 3,027,326 warrants to acquire common stock with exercise prices ranging from \$4.00 to \$5.50 expired unexercised

During the quarter ended June 30, 2003, the Company granted 2,000,000 options to certain directors to purchase shares of common stock with an exercise price of \$0.03 per share, which was equal to the closing market price of the common stock on the date of grant. These options vest through 2006.

### (7) Commitments and Contingencies

#### Employment Contract

The Company has a five-year employment contract with the Company's president. The employment agreement extends through February 2007.

#### Lease Agreement

Effective May 2, 2003, the Company entered into a new lease agreement with the landlord for a new five year term on the building. This new lease offers the same terms and first rights to purchase considerations that existed in the previous lease agreement but increase monthly lease rate and purchase price by an amount proportional to the square footage of the new facility expansion.

#### Dependence on Third Parties

The production of HSA Cobalt is dependent upon the Department of Energy, and its prime-operating contractor, who controls the reactor and laboratory operations. Actions by the DOE or their prime operating contractor could cause a halt to HSA cobalt production, which would result in a loss of revenues to the Company and a

## Edgar Filing: INTERNATIONAL ISOTOPES INC - Form 10QSB

loss of the value of all Work in Process cobalt material. The gemstone production is tied to an exclusive agreement with Quali Tech Inc. who in turn has contracts with other clients for gemstone processing. A loss of the contract with Quali Tech Inc. would require the Company to seek other clients for gemstone processing. Nuclear medicine calibration and reference standards manufacturing is conducted under an exclusive contract with RadQual, LLC, which in turn has agreements in place with several companies for marketing and sales. A loss of the contract with RadQual LLC would cause a complete loss of the revenues from nuclear medicine calibration and reference standards.

### Contingencies

The Company conducts its operations in Idaho Falls, Idaho. Although the nuclear medicine calibration and reference standards and gemstone products appear diverse they share the common link of being radioactive materials requiring stringent quality controls. Therefore, the Company is required to have an operating license from the Nuclear Regulatory Commission ("NRC") and specially trained staff to handle these products. An irrevocable, automatic renewable letter of credit against a Certificate of Deposit has been used to provide decommissioning financial assurance as required by the Nuclear Regulatory Commission for the facility license.

### (8) Subsequent Events

The Company has filed an S-3 Registration Statement with the Securities and Exchange Commission (SEC) in connection with a rights offering to its existing shareholders. The Registration Statement is anticipated to become effective in the third quarter of 2003. Pursuant to the rights offering the Company is offering for sale 38,229,157 Units (each Unit includes (i) one share of common stock, (ii) one warrant to purchase another share of common stock for \$0.04, and (iii) one warrant to purchase an additional share of common stock for \$0.05) to its shareholders. Shareholders will receive one Right for each share of common stock they own. The Rights entitle the holders to purchase one Unit for every 2.5 Rights owned at a subscription price of \$0.03 per unit. Shareholders who exercise all of their Rights in full will be entitled to the additional privilege of subscribing for and purchasing, subject to certain limitations and subject to allocation, any Units not acquired by other holders of Rights, plus up to an additional 14,500,000 Units if the rights offer is over-subscribed.

## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Except for historical information contained herein, the following contains forward-looking information that is subject to certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors including those set forth in the "Risk Factors" section included in the Company's Form 10-KSB, filed with the Securities Exchange Commission (SEC) on March 24, 2003 ("Form 10-KSB"). The following discussion should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in the Form 10-KSB.

10

### RESULTS OF OPERATIONS

Three and six month periods ended June 30, 2003 and 2002.

## Edgar Filing: INTERNATIONAL ISOTOPES INC - Form 10QSB

The Company's loss from operations for the three and six month periods ended June 30, 2003 were \$74,851 and \$333,578 respectively, as compared to earnings from continuing operations of \$228,403 and \$259,348 for the comparable periods of 2002. The change in earnings was principally attributable to the one time removal of the \$500,000 contingent liability the Company had in connection with the sale of the Linac facility in Denton Texas. During the second quarter of 2002 the Company was released from this contingent liability and recognized this transaction in other income. Without this one time event, the Company would have experienced losses from operations of \$271,597 and \$589,894 for the three and six months periods respectively ended June 30, 2002. Net earnings (loss) per common share for the three and six month periods ended June 30, 2003 were \$0.00 and \$0.00 respectively, as compared to \$0.00 and \$0.00 for the same periods of 2002. The reason there is no change in this figure is related to rounding. Both the 2002 income and 2003 loss are relatively small in comparison to the number of outstanding shares of Company stock.

Revenues for the three and six month periods ended June 30, 2003 were \$785,262 and \$1,144,683 respectively, as compared to \$624,084 and \$1,150,396 for the same periods in 2002, an increase of \$161,178 and decrease of \$5,713 respectively. Gross profit for the three and six month periods ended June 30, 2003 was \$354,695 and \$503,033 respectively, as compared to \$252,662 and \$578,156 for the same periods in 2002, an increase of \$102,033 and a decrease of \$75,123 respectively. The increase in revenue and Gross profit for the three-month period was attributable to increased sales of nuclear medicine reference and calibration standards. The decrease in revenues and Gross profit for the six-month period was attributable to an overall decline in gemstone production volumes.

Operating expenses declined to \$401,534 and \$790,316 respectively for the three and six-month periods ended June 30, 2003 compared to \$543,419 and \$795,907 for the same periods of 2002. Salaries and contract labor expenses for the three and six month periods ended June 30, 2003 were \$110,982 and \$213,752 respectively, as compared to \$117,765 and \$255,080 for the same periods of 2002, a decrease of \$6,783 and \$41,328 respectively. General, administrative and consulting expenses totaled \$290,552 and \$576,564 respectively for the three and six month periods ended June 30, 2003 as compared to \$425,654 and \$540,827 for the same periods of 2002, a decrease of \$135,102 and an increase of \$35,737 respectively. The overall decrease in expenses is largely attributable to the Company's efforts to control costs.

Interest expense for the three and six month period ended June 30, 2003 was \$50,281 and \$82,199 as compared to \$44,669 and \$88,611 for the comparable periods in 2002. The increase in second quarter interest expense was attributable to the short term loans made to the Company by several Principals and Directors during the period.

### Liquidity and Capital Resources

On June 30, 2003 the Company had cash and cash equivalents of \$824,518 compared to \$441,904 at December 31, 2002. For the six months ended June 30, 2003, operating activities used cash of \$264,325, investing activities provided cash of \$159,322 and financing activities provided cash of \$487,617. Cash from financing activities consisted primarily of short-term notes provided by several principals and directors.

The Company has financed its operations since inception primarily by bank loans, sales of accelerator components and excess equipment, its initial public

## Edgar Filing: INTERNATIONAL ISOTOPES INC - Form 10QSB

offering, sales of shares of common and preferred stock in private placements to investors, and loans from stockholders and directors.

The Company's future liquidity and capital funding requirements will depend on numerous factors, including, but not limited to: sale of remaining Texas assets, contract manufacturing and marketing relationships; and technological and market developments. It is anticipated that the rights offering will convert a significant amount of the Company's current liabilities to equity and generate cash to be used for the acquisition of assets. This should improve the Company's financial strength, debt ratio, and attractiveness to lending institutions.

Although there can be no assurance, the Company expects that revenues will continue to increase. These increased revenues will provide sufficient funds for operations and capital expenditures.

### ITEM 3. CONTROLS AND PROCEDURES

(a) The Company maintains controls and procedures designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. Based upon their evaluation of those controls and procedures performed within 90 days of the filing date of this report, the chief executive officer and the principal financial officer of the Company concluded that the Company's disclosure controls and procedures were adequate.

(b) Changes in internal controls. The Company made no significant changes in its internal controls or in other factors that could significantly affect these controls subsequent to the date of the evaluation of those controls by the chief executive officer and principal financial officer.

### PART II. OTHER INFORMATION

#### Item 6. Exhibits and Reports on Form 8-K

##### Exhibits:

99.1 Certification pursuant to 18 U.S.C. ss.1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

99.2 CEO and CFO Certification

##### Reports on Form 8-K:

NONE

Edgar Filing: INTERNATIONAL ISOTOPES INC - Form 10QSB

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

International Isotopes Inc.  
(Registrant)

By: /s/ Steve T. Laflin

-----  
Steve T. Laflin  
President and Chief Executive Officer

Date: July 28, 2003

13

TABLE OF EXHIBITS

| Exhibit Number | Name of Exhibit  |
|----------------|--|
| 99.1           | Certification pursuant to 18 U.S.C. ss.1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 99.2           | CEO and CFO Certification  |

14